Skip to content

Study · In vitro (cells) · 1992

5 results

des-(1-3)-IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells.

Remacle-Bonnet M, Garrouste F, el Atiq F, Roccabianca M, Marvaldi J, Pommier G

International journal of cancer1 Dec 1992Cited by 35 (Europe PMC)

PMID1281142 (opens in a new tab)DOI10.1002/ijc.2910520614 (opens in a new tab)PepBankPUB-01281142
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In HT29-D4 cells, type-I IGF receptors bound des-(1-3)-IGF-I and IGF-I identically.

    In plain wordsIn cells, des-(1-3)-IGF-I and IGF-I bound type-I IGF receptors equally.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeType-I IGF receptor binding
    Study

    humann: not reported in source

    HT29-D4 colon-carcinoma cells
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Measurements

    KD
    5 x 10(-10) M
    approximately, type-I IGF receptors binding des-(1-3)-IGF-I and IGF-I

    Source sentences

    Summary
    In contrast, HT29-D4 cell-surface type-I IGF receptors bind IGF-I and des-(1-3)-IGF-I identically (KD approx. 5 x 10(-10) M).
  2. 02LabIn vitro (cells)Efficacy outcome

    In HT29-D4 cells, des-(1-3)-IGF-I induced differentiation with substantial carcinoembryonic antigen release.

    In plain wordsIn cells, des-(1-3)-IGF-I promoted differentiation with substantial carcinoembryonic antigen release.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseCarcinoembryonic antigen release
    Study

    humann: not reported in source

    HT29-D4 colon-carcinoma cells
    Outcome group
    Cell proliferation and differentiation · Cancer
    Studied dose
    Nanomolar concentrationsAs given in this study (human).

    Source sentences

    Summary
    Nanomolar concentrations of des-(1-3)-IGF-I induce HT29-D4 cells to develop into a differentiated phenotype, as judged by a substantial carcinoembryonic antigen release and the induction of numerous intercellular cysts with well-organized microvilli.
  3. 03LabIn vitro (cells)Efficacy outcome

    In HT29-D4 cells, des-(1-3)-IGF-I induced numerous intercellular cysts with well-organized microvilli.

    In plain wordsIn cells, des-(1-3)-IGF-I induced intercellular cysts with organized microvilli.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseIntercellular cyst formation
    Study

    humann: not reported in source

    HT29-D4 colon-carcinoma cells
    Outcome group
    Cell proliferation and differentiation · Cancer
    Studied dose
    Nanomolar concentrationsAs given in this study (human).

    Source sentences

    Summary
    Nanomolar concentrations of des-(1-3)-IGF-I induce HT29-D4 cells to develop into a differentiated phenotype, as judged by a substantial carcinoembryonic antigen release and the induction of numerous intercellular cysts with well-organized microvilli.
  4. 04LabIn vitro (cells)Efficacy outcome

    In HT29-D4 cells, des-(1-3)-IGF-I induced a slight early inhibition of proliferation.

    In plain wordsIn cells, des-(1-3)-IGF-I slightly inhibited early colon cancer cell proliferation.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseCell proliferation
    Study

    humann: not reported in source

    HT29-D4 colon-carcinoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the same way, des-(1-3)-IGF-I early induces a slight inhibition of HT29-D4 cell proliferation.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 05LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Activity measurement

    In HT29-D4 cultures, none of the secreted IGFBP molecular forms bound des-(1-3)-IGF-I.

    In plain wordsIn lab tests, the binding proteins secreted by HT29-D4 cells did not bind des-(1-3)-IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicableIGFBP binding
    Study

    humann: not reported in source

    HT29-D4 colon-carcinoma cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    All the HT29-D4 IGFBP molecular forms are unable to bind the N-terminally truncated IGF-I analog, des-(1-3)-IGF-I.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.